Ally Bridge Group

2013

Founded

67

Investments

Hong Kong

Offices

Venture Fund

Investor Type

About

Ally Bridge Group is a global healthcare investment management firm specializing in high-impact life science innovation. Founded in 2013 by Frank Yu, the firm operates from offices in New York and Hong Kong. Since its inception, Ally Bridge Group has led or co-led over $6 billion in transactions across various healthcare subsectors.

The firm's mission is to generate superior -adjusted returns for investors while addressing unmet medical needs. This is achieved by combining deep scientific and clinical research with proven M&A and capital markets expertise. Ally Bridge Group employs two complementary investment strategies: private equity, established in 2013, and public equity, launched in 2018.

By leveraging its global presence and local talent, the firm seeks to identify and secure opportunities in high-impact life science innovation. (

Investment Focus

HQ Locations

Portfolio Companies

Aerin Medical, Arbor Biotechnologies, BenevolentAI, LightForce Orthodontics, Ceribell, Endeavor BioMedicines, Transcarent, Shoreline Biosciences, Quantum Surgical, Elligo Health Research

Gepgraphic Focus

Global

Key Differentiators

Global presence with offices in New York and Hong Kong, Expertise in both private and public equity strategies, Focus on high-impact life science innovation

Thypical Investment Size

Not publicly disclosed

Total Funds Raised

Over $6 billion

Visit Website

BioTech

Hong Kong

Seed

Series A

Series B

Series C

Series D

Hong Kong